Hepatitis B virus genotypes in the United States: results of a nationwide study
…, SH Han, RP Perrillo, AD Min, C Soldevila-Pico… - Gastroenterology, 2003 - Elsevier
BACKGROUND & AIMS:: Hepatitis B virus (HBV) genotypes may be related to severity of liver
disease and treatment response. The aims of this nationwide study were to determine the …
disease and treatment response. The aims of this nationwide study were to determine the …
[PDF][PDF] Betaine for nonalcoholic fatty liver disease: results of a randomized placebo‐controlled trial
…, SO Sanderson, P Angulo, C Soldevila‐Pico… - …, 2009 - Wiley Online Library
Based on animal studies and pilot studies in humans, betaine, a methyl donor for the
remethylation of homocysteine, may be a therapeutic agent for nonalcoholic steatohepatitis (NASH)…
remethylation of homocysteine, may be a therapeutic agent for nonalcoholic steatohepatitis (NASH)…
Prevalence of HBV precore/core promoter variants in the United States
…, SH Han, RP Perrillo, AD Min, C Soldevila-Pico… - Hepatology, 2003 - Elsevier
Variants in the precore (G 1896 A) and core promoter (A 1762 T, G 1764 A) regions of hepatitis
B virus (HBV) may be related to serum HBV DNA levels and severity of liver disease. The …
B virus (HBV) may be related to serum HBV DNA levels and severity of liver disease. The …
Long–Term Interleukin 10 Therapy in Chronic Hepatitis C Patients Has A Proviral and Anti–Inflammatory Effect
DR Nelson, Z Tu, C Soldevila-Pico, M Abdelmalek… - Hepatology, 2003 - journals.lww.com
An imbalance in Th1 and Th2 cytokine production is implicated in disease progression of
HCV. Our aim was to determine the effect of IL–10 administration in patients with HCV–related …
HCV. Our aim was to determine the effect of IL–10 administration in patients with HCV–related …
Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes
…, VC Clark, R Lomonaco, C Soldevila-Pico… - Clinical …, 2018 - Elsevier
Background & Aims Pioglitazone is effective for long-term treatment of patients with nonalcoholic
steatohepatitis (NASH) with prediabetes or type 2 diabetes. However, it is not clear how …
steatohepatitis (NASH) with prediabetes or type 2 diabetes. However, it is not clear how …
[HTML][HTML] Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma
…, DR Nelson, C Soldevila-Pico… - Oncology …, 2013 - spandidos-publications.com
The aim of the present study was to determine the treatment outcome and prognostic factors
for survival in patients with peripheral intrahepatic cholangiocarcinoma (ICC). A …
for survival in patients with peripheral intrahepatic cholangiocarcinoma (ICC). A …
[PDF][PDF] One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
RJ Firpi, MF Abdelmalek, C Soldevila‐Pico… - Liver …, 2004 - Wiley Online Library
Determinants of progression to cirrhosis in hepatitis C virus (HCV) infection have been well
described in the immunocompetent population but remain poorly defined in liver transplant (…
described in the immunocompetent population but remain poorly defined in liver transplant (…
[PDF][PDF] Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation
…, MF Abdelmalek, C Soldevila‐Pico… - Liver …, 2006 - Wiley Online Library
Cyclosporine is an immunosuppressive agent widely used in the management of liver transplant
recipients. Cyclosporine has been shown to have antiviral activities against HIV, herpes …
recipients. Cyclosporine has been shown to have antiviral activities against HIV, herpes …
[PDF][PDF] The natural history of hepatitis C cirrhosis after liver transplantation
RJ Firpi, V Clark, C Soldevila‐Pico… - Liver …, 2009 - Wiley Online Library
Hepatitis C after liver transplantation leads to graft cirrhosis in up to 30% of patients within 5
years, but limited data exist regarding the clinical course of cirrhosis after transplantation. …
years, but limited data exist regarding the clinical course of cirrhosis after transplantation. …
[HTML][HTML] Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation
…, RS Brown Jr, S Emre, C Soldevila-Pico… - American journal of …, 2010 - Elsevier
The availability of hepatitis B immune globulin (HBIG) and several oral antiviral therapies has
reduced but not eliminated hepatitis B virus (HBV) recurrence. We aimed to determine the …
reduced but not eliminated hepatitis B virus (HBV) recurrence. We aimed to determine the …